A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants with Amyotrophic Lateral Sclerosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARGX-119 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Proof of concept
Acronyms ReALiSe
Sponsors argenx

Most Recent Events

13 Jan 2025 According to an argenx media release, Phase 2a proof-of-concept study ongoing in ALS; topline results expected in first half of 2026.
30 Oct 2024 Planned End Date changed from 1 May 2027 to 1 Jul 2027.
30 Oct 2024 Planned primary completion date changed from 1 May 2027 to 1 Jul 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight